Rachel Harris Appointed to Plantiff’s Steering Committee in Eliquis Products Liability Litigation
Schlichter Bogard & Denton is pleased to announce that Rachel Harris has been appointed to the Plaintiffs’ Steering Committee (PSC) in the Eliquis (Apixaban) Products Liability Litigation pending in the U.S. District Court for the Southern District of New York (MDL 2754, Case Management Order 1). The presiding judge, The Honorable Denise Cote, selected Rachel to help lead this national litigation.
The PSC is a committee of experienced attorneys responsible for working with Lead Counsel on strategic decision-making on behalf of all plaintiffs in the nationwide litigation. As a member of the PSC, Rachel Harris will perform vital and exclusive functions, which include initiating and coordinating pretrial activities, planning for trial of these cases, and advocating on behalf of all plaintiffs.
Eliquis is a popular prescription blood-thinning medication. The Eliquis lawsuits allege permanent injuries, including serious and uncontrollable internal bleeding events. These lawsuits claim that the drug manufacturers Bristol-Myers Squibb, Pfizer, and their related corporate entities failed to warn patients and their physicians about the life-threatening side effects associated with Eliquis.
Schlichter Bogard & Denton is a unique law firm that has held numerous leadership positions in nationwide litigations involving dangerous pharmaceutical medications, unsafe medical devices, and toxic torts, including but not limited to: In re: Invokana Products Liability Litigation (MDL 2750, D. N.J.), In re: Bair Hugger Forced Air Warming Devices Products Liability Litigation (MDL 2666, D. Minn.), In re: Testosterone Replacement Therapy Products Liability Litigation (MDL 2545, N.D. Ill.), In re: Pradaxa® (Dabigatran Etexilate) Products Liability (MDL 2385, S.D. Ill.), In re: E.I. Du Pont de Nemours and Company C-8 Personal Injury Litigation (MDL 2433, S.D. Ohio), In re: Yasmin® and Yaz® (Drospirenone) Marketing and Sales Practices and Products Liability Litigation (MDL 2100, S.D. Ill.), In re: NuvaRing® Products Liability Litigation (MDL 1964, E.D. Mo.), In re: Gadolinium-Based Contrast Products Liability Litigation (MDL 1909, N.D. Ohio), and In re: Ortho Evra® Products Liability Litigation (MDL 1742, N.D. Ohio).
If you or a loved one has suffered serious injuries after using Eliquis, contact the attorneys at Schlichter Bogard & Denton toll-free at 1-800-873-5297 for your free and confidential case evaluation.
The choice of a lawyer is an important decision and should not be based solely on advertisement. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case must be judges on its own merits.
